For a stock to ascend, favorable earnings estimate revisions are crucial, a domain where the Zacks Rank shines. Leveraging four factors tied to earnings estimates, the Zacks Rank categorizes stocks into five brackets, spanning from ‘Strong Buy’ to ‘Strong Sell.’ This mechanism empowers individual investors to capitalize on trends in earnings estimate revisions and leverage the insights of institutional investors.
Stride LRN: Soaring to New Heights
Stride stands as a leading provider of K-12 education services, encompassing career learning offerings within middle and high school curricula. Boasting a Zacks Rank #1 (Strong Buy), the stock revels in elevated earnings projections across the board.
Impressive quarterly achievements have propelled LRN shares skyward this year, ascending by 16% in 2024 against the S&P 500’s 12% uptick. Surpassing the Zacks Consensus EPS estimate by an average of 42% over the last four quarters, the company’s operational efficiencies have paved the way for significant margin expansion, heightening profitability levels.
Interactive Brokers IBKR: Navigating a +50% Growth Trajectory
IBKR has exhibited remarkable strength this year, recording a +50% surge, juxtaposed with the S&P 500’s commendable 12% progress. Following a set of stellar quarterly outcomes, the stock has ascended to a Zacks Rank #1 (Strong Buy) as analysts revise earnings expectations upward.
Breaking a spell of mixed earnings results, IBKR saw a 21% increase in earnings and a 25% growth in revenue. Maintaining robust revenue expansion, the company has sustained double-digit year-over-year sales growth rates across its past seven periods.
Haemonetics HAE: Sustained Growth Trajectory
Haemonetics offers blood management solutions to a global clientele, spanning blood and plasma collectors, hospitals, and healthcare providers. Reflecting heightened expectations, analysts have boosted the stock to a Zacks Rank #1 (Strong Buy).
Similar to IBKR, the company has experienced notable revenue escalation, securing double-digit year-over-year sales growth in nine of its last ten periods. Projections paint a picture of continued robust growth, with anticipations for the current fiscal year pointing towards a 15% surge in earnings on 7% higher sales.
The Power of Positive Revisions
Sticking to the Zacks Rank methodology often leads to market-beating returns, with optimistic earnings estimate revisions acting as the propeller for stock ascension. All three luminaries – Stride LRN, Interactive Brokers IBKR, and Haemonetics HAE – currently bask in a Zacks Rank #1 (Strong Buy), underlining the upward trend in earnings estimate revisions.
Curious to learn more about leveraging this time-tested system for outperformance? Visit Zacks Rank Education for further insights.
